Stacey A. Taylor

Statistics

Publications

Citations

H-Index

Active since

2007

Affiliations

Stacey A. Taylor is an author at AIL Research (United States) specializing in cancer pharmacology, pharmacology, and cancer cell proliferation inhibition.

Publications per year

2007–2018

Publications

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

Sobhana Babu Boga, Yongqi Deng, Liang Zhu et al. · ACS Medicinal Chemistry Letters · 2018 · 51 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo

Stacey A. Taylor, Cindy H. Marrinan, Gongjie Liu et al. · Gynecologic Oncology · 2008 · 19 citations

Medicine, Oncology, Pharmacology +13

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)

Gonjgie Liu, Cindy H. Marrinan, Stacey A. Taylor et al. · Anti-Cancer Drugs · 2007 · 17 citations

Medicine, Oncology, Pharmacology +16

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

Gongjie Liu, Stacey A. Taylor, Cindy H. Marrinan et al. · International Journal of Cancer · 2009 · 11 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

1–4 of 4